Breast Cancer

Breast cancer is a malignant condition characterized by the uncontrolled growth of cells within breast tissue — most commonly originating in the ducts (ductal carcinoma) or lobules (lobular carcinoma). It is the most common cancer in women worldwide and a leading cause of cancer-related mortality, though outcomes have improved significantly with early detection and advances in treatment.

Breast cancer is not a single disease but a biologically diverse group of tumors with distinct molecular subtypes, risk profiles, and treatment responses. These differences are largely defined by the presence or absence of hormone receptors (estrogen and progesterone) and HER2 expression, which guide both prognosis and therapy.

Early identification through screening and prompt diagnostic evaluation is critical, as breast cancer is highly treatable — and often curable — when detected at an early stage.

How Breast Cancer Develops

Normal breast cells grow and divide in a regulated manner. Breast cancer develops when genetic mutations disrupt this regulation, leading to uncontrolled proliferation and the potential to invade surrounding tissue and metastasize.

Key biological pathways involved include:

Hormonal signaling — estrogen and progesterone can stimulate tumor growth in hormone receptor-positive cancers
HER2 signaling — overexpression leads to aggressive tumor growth
DNA repair pathways — mutations (e.g., BRCA1/2) impair genomic stability

Cancer progression typically follows stages:

In situ disease (e.g., ductal carcinoma in situ, DCIS) — confined to ducts
Invasive cancer — spreads into surrounding breast tissue
Metastatic disease — spreads to distant organs (bone, liver, lungs, brain)

Types and Molecular Subtypes

Histological types

Ductal carcinoma (most common)
Lobular carcinoma
Less common: inflammatory breast cancer, Paget’s disease

Molecular subtypes (clinically critical)

Subtype	Characteristics	Clinical significance
Hormone receptor-positive (ER+/PR+)	Estrogen and/or progesterone driven	Most common; responds to hormone therapy
HER2-positive	Overexpression of HER2 protein	More aggressive; responsive to targeted HER2 therapies
Triple-negative (ER-, PR-, HER2-)	Lacks all three receptors	More aggressive; limited targeted therapy options

Risk Factors

Non-modifiable

Female sex
Increasing age
Genetic mutations (e.g., BRCA1, BRCA2)
Family history of breast or ovarian cancer
Early menarche / late menopause (prolonged estrogen exposure)

Modifiable and hormonal

Obesity (especially postmenopausal)
Alcohol consumption
Hormone replacement therapy (particularly combined estrogen-progesterone)
Physical inactivity

Reproductive factors

Nulliparity (never having given birth)
Late age at first pregnancy
Lack of breastfeeding

Symptoms and Clinical Signs

Early breast cancer is often asymptomatic, which is why screening is critical.

When present, symptoms may include:

Breast lump or thickening
Change in breast size or shape
Skin changes (dimpling, redness, “peau d’orange”)
Nipple discharge (especially bloody)
Nipple inversion
Persistent breast or axillary pain

Advanced disease may present with systemic symptoms depending on metastasis.

Screening and Early Detection

Mammography

Primary screening tool
Detects cancers before symptoms develop
Recommended starting age varies by guideline (typically 40–50)

Additional imaging

Breast ultrasound — useful in dense breast tissue
MRI — for high-risk individuals (e.g., BRCA mutation carriers)

Clinical and self-examination

Clinical breast exams may aid detection
Breast self-awareness is encouraged, though not a replacement for screening

Diagnostic Evaluation

If abnormalities are detected:

Diagnostic mammography and ultrasound
Core needle biopsy (definitive diagnosis)
Pathology determines tumor type, grade, and receptor status (ER, PR, HER2)

Laboratory and Biomarker Assessment

While breast cancer is primarily diagnosed via imaging and biopsy, certain biomarkers are essential for management:

Tumor markers (tissue-based)

Marker	Role
Estrogen receptor (ER)	Determines hormone sensitivity
Progesterone receptor (PR)	Supports hormone responsiveness
HER2	Guides targeted therapy decisions
Ki-67	Proliferation index (tumor aggressiveness)

Blood-based markers (limited role)

CA 15-3, CA 27-29 — used in monitoring advanced disease (not for screening)

Genetic testing

BRCA1 / BRCA2 and other hereditary cancer genes
Important for risk assessment and treatment planning

Staging

Breast cancer staging is based on:

Tumor size (T)
Lymph node involvement (N)
Metastasis (M)

Stages range from:

Stage 0 (in situ)
Stage I–III (localized to regional spread)
Stage IV (metastatic)

Treatment Overview

Treatment depends on tumor subtype, stage, and patient-specific factors.

Surgery

Lumpectomy (breast-conserving)
Mastectomy
Sentinel lymph node biopsy or axillary dissection

Radiation therapy

Often used after surgery to reduce recurrence risk

Systemic therapies

Hormone therapy (for ER+/PR+ cancers)

Tamoxifen
Aromatase inhibitors
Suppresses estrogen-driven tumor growth

Chemotherapy

Used in higher-risk or aggressive cancers
Targets rapidly dividing cells

Targeted therapy

HER2-targeted agents (e.g., trastuzumab)
Highly effective in HER2-positive disease

Immunotherapy

Used in selected cases (e.g., triple-negative breast cancer)

Prognosis

Prognosis depends on:

Stage at diagnosis (most important factor)
Tumor subtype
Response to therapy

Early-stage breast cancer has a high survival rate, while metastatic disease remains treatable but generally not curable.

When to Seek Evaluation

New breast lump or persistent breast change
Nipple discharge or inversion
Skin changes on the breast
Strong family history of breast or ovarian cancer
Any abnormal screening result

Summary

Breast cancer is a common but highly heterogeneous disease, ranging from slow-growing hormone-sensitive tumors to aggressive subtypes such as triple-negative or HER2-positive cancers. Early detection through screening remains the most important factor in improving outcomes.

Diagnosis is based on imaging and biopsy, with molecular characterization (ER, PR, HER2) guiding treatment decisions. Management typically involves a combination of surgery, radiation, and systemic therapies tailored to tumor biology.

With advances in screening, targeted therapies, and personalized medicine, breast cancer outcomes have improved significantly — particularly when diagnosed at an early stage.